clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - chlorowodorek klopidogrelu - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - Środki przeciwzakrzepowe - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
rapilysin
actavis group ptc ehf - reteplase - zawał mięśnia sercowego - Środki przeciwzakrzepowe - rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (ami) symptoms.
kybernin p 50 j.m./ml; 500 j.m./10 ml proszek i rozpuszczalnik do sporządzania roztworu do infuzji
csl behring gmbh - antithrombinum iii - proszek i rozpuszczalnik do sporządzania roztworu do infuzji - 50 j.m./ml; 500 j.m./10 ml
metex 50 mg/ml roztwór do wstrzykiwań
medac gesellschaft für klinische spezialpräparate mbh - methotrexatum natricum - roztwór do wstrzykiwań - 50 mg/ml
metotab 2,5 mg 2,5 mg tabletki
medac gesellschaft für klinische spezialpräparate mbh - methotrexatum - tabletki - 2,5 mg
metotab 7,5 mg 7,5 mg tabletki
medac gesellschaft für klinische spezialpräparate mbh - methotrexatum - tabletki - 7,5 mg
metotab 10 mg 10 mg tabletki
medac gesellschaft für klinische spezialpräparate mbh - methotrexatum - tabletki - 10 mg
diclovit - kapsułki twarde
g.l. pharma gmbh - diclofenacum natricum + thiamini hydrochloridum + pyridoxini hydrochloridum + cyanocobalaminum - kapsułki twarde - -
methofill 2,5 mg tabletki
accord healthcare polska sp. z o.o. - methotrexatum - tabletki - 2,5 mg
methofill 10 mg tabletki
accord healthcare polska sp. z o.o. - methotrexatum - tabletki - 10 mg